Trending
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Capital, M&A & Industry Strategy7 hours agoFDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed...
-
Global Biotechnology & Pharmaceutical Markets12 hours agoWCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability...
-
Global Biotechnology & Pharmaceutical Markets12 hours agoEnsuring safety and accountability in China’s biomedical translation system
Nature Biotechnology, Published online: 15 September 2026; doi:10.1038/s41587-026-03314-xChina’s Decree 818 aims to bring hospital-based cell, gene and individualized therapies into the clinic safely. Its success will...
-
Helixgate Featured14 hours agoFDA launches pilot program to speed up early US drug research
First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines...
-
Regulatory Intelligence & Drug Approvals14 hours agoSTAT+: Obesity drugmakers are testing in kids as young as 6
Vera seeks kidney drug approval, early data from Syntis Bio, and other biotech news from The Readout
-
Clinical Trials & Development14 hours agoFDA launches pilot program to speed up sluggish phase 1 trials
After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program for an expedited investigational new...
-
Capital, M&A & Industry Strategy15 hours agoElectra sets terms for IPO, hoping to raise up to $347m
Electra Therapeutics has moved ahead with plans for an IPO, seeking to raise funds for its drug for the rare and life-threatening disease sHLH.
-
Global Biotechnology & Pharmaceutical Markets16 hours agoGSK wagers $750m on Chimagen multiple myeloma therapy
GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.
-
Clinical Trials & Development17 hours agoSTAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
The drug stabilized kidney function and reduced the risk of death and other complications in IgAN patients
-
Regulatory Intelligence & Drug Approvals18 hours agoFDA to decide on Takeda’s psoriasis blockbuster hope in Q1
The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
